I
n conclusion, stool transplantation is a safe and effective clinical
treatment option for patients suffering from RCDI. Advantages of this
treatment include its high cure rates, and the reliance on “the ultimate
probiotic” e healthy stool flora e for restoring intestinal microbiota
and colonization resistance. Even though the cost of FMT at present
includes the cost of laboratory screening of the stool donors, the
overall cost will likely be far lower than the costs for alternative
therapies, which include repeated hospitalizations and treatment
courses with expensive antibiotic agents. If the costs of laboratory
screening of donors could be reduced or eliminated, FMT could be
made financially more accessible to a wider range of patients.